证券之星消息，8月12日化妆品板块较上一交易日下跌0.02%，上海家化领跌。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。化妆品板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603630 拉芳家化 | | -2328.54万 | 8.07% | 1048.31万 | 3.63% | -3376.86万 | -11.70% | | 603605 | | 1580.14万 | 3.82% | -930.55万 | -2.25% | -649.59万 | -1.57% | | 300132 青松股份 | | 891.73万 | 5.74% | 1094.90万 | 7.05% | -1986.64万 | -12.79% | | 603983 丸美生物 | | 741.71万 | 7.38% | -407.62万 | -4.06% | -334.09 ...

证券之星消息，8月8日化妆品板块较上一交易日下跌0.91%，芭薇股份领跌。当日上证指数报收于 3635.13，下跌0.12%。深证成指报收于11128.67，下跌0.26%。化妆品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603630 | 拉芳家化 | 24.72 | 1.06% | 15.70万 | 3.82亿 | | 300955 | 嘉亨家化 | 20.80 | 1.02% | 4.09万 | 8439.97万 | | 600223 | 福瑞达 | 8.43 | -0.12% | 10.99万 | 9216.76万 | | 300856 | 科思股份 | 15.25 | -0.33% | - 3.09万 | 4711.62万 | | 603605 | 班莱雅 | 82.58 | -0.37% | 3.51万 | 2.90亿 | | 301371 | 敷尔佳 | 26.60 | -0.45% | 2.33万 | 6187.52万 | | 300849 | 锦盛新材 ...

Core Insights - The total salary scale for CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - The highest annual salary for a CFO in the beauty and skincare industry was 2.933 million yuan, paid to Wang Li of Proya [2][3] - There are nearly 12 listed companies in the beauty and skincare sector where CFO salaries exceed 1 million yuan [2] Salary Overview - The average annual salary for CFOs in the beauty and skincare industry is 770,000 yuan [1] - The highest salaries among CFOs in this sector include: - Proya: 2.933 million yuan - Betaini: 2.82 million yuan - Aimeike: 2.335 million yuan - Baiya: 2.048 million yuan - Sturdy Medical: 2.015 million yuan [2][3] Company Performance - Qing Song Co.'s CFO, Wang Yucai, has seen the company's revenue decline for four consecutive years, with net profit once falling into the red [1][4] - Sturdy Medical's accounts receivable growth rate outpaced revenue growth, leading to a rising accounts receivable to revenue ratio and declining gross profit margin [3] - Aimeike experienced a significant slowdown in revenue and net profit growth, with multiple profitability indicators declining [3][4] - Betaini reported increased revenue but decreased profitability, with several operational capability indicators also declining [4] Age Demographics of CFOs - The youngest CFOs in the industry are Wang Yucai from Qing Song Co. and Zou Fei from Shui Yang Co., both aged 35 [4] - The oldest CFO is Dong Ye from Zhongshun Jierou, aged 61 [4]

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 随着年报披露收官，美容护肤行业上市公司财务总监薪酬面纱也被揭开。据数据统计，美容护肤行业上 市公司年薪为77万元，其中为财务总监支付的最高年度薪酬是珀莱雅，为财务总监王莉支付年薪293.3 万元；为CFO支付的最低年度薪酬是两面针，为原财务总监王为民支付年薪34.26万元。 美容护肤行业财务总监薪酬有近12家上市公司的财务薪酬超百万，分别为青松股份、锦波生物、登康口 腔、力合科创、华熙生物、中顺洁柔、稳健医疗、百亚股份、爱美客、华熙生物、贝泰妮、珀莱雅，这 些上市公司分别给财务总监支付年薪115万元、115.7万元、125.78万元、132.08万元、158.77万元、 168.41万元、201.5万元、204.78万元、233.5 ...

Group 1 - The number of confirmed cases of Chikungunya fever in Shunde, Guangdong has reached 2,934, primarily affecting Lecong, Beijiao, and Chen Village, all of which are mild cases [1][2] - The World Health Organization has issued a warning regarding the potential for widespread outbreaks of Chikungunya fever, with 119 countries and regions reporting cases, putting approximately 5.5 million people at risk [2][3] - Local governments in Guangdong are actively promoting mosquito control measures, including public announcements urging citizens to eliminate mosquito breeding sites and participate in coordinated mosquito eradication efforts [2][3] Group 2 - The "mosquito repellent concept" has gained traction in the capital markets, with stocks related to mosquito control and testing reagents seeing significant increases [5][6] - Companies such as Rainbow Group and Kangzhi Pharmaceutical have experienced stock price surges, while others like Runben Co., Shanghai Jahwa, and Qingsong Co. have also seen gains [6] - Several companies, including Rendu Biotech and Mindray, have highlighted their mosquito-borne virus testing products, indicating a growing market interest in diagnostic tools for diseases like Chikungunya [6]

Core Viewpoint - The mosquito-repellent concept stocks continue to show strong performance, driven by the reported cases of Chikungunya fever in Foshan, with a total of 3,195 confirmed cases as of July 22, primarily concentrated in Shunde District [1] Group 1: Company Performance - Rainbow Group has achieved a consecutive two-day increase in stock price [1] - Kangzhi Pharmaceutical has seen a rise of over 10% in its stock price [1] - Other companies such as Runben Co., Wanfang Biological, Shanghai Jahwa, Qingsong Co., and Lafang Co. have also experienced stock price increases [1]

Financial Performance - In 2024, the company's operating revenue was 1.94 billion, a year-on-year decrease of 1.51% [2] - The net profit attributable to shareholders was 54.68 million, an increase of 180.02% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 55.40 million, reflecting a year-on-year increase of 201.95% [2] Employee Statistics - The total number of employees at the end of 2024 was 4,878, an increase of 8.74% from 4,486 in the previous year, adding 392 employees [4] - The number of employees in the parent company was 84, while the subsidiaries employed 4,794 [4] Executive Compensation - The compensation for the chairman and CEO, Fan Zhanhua, increased from 175,000 in 2020 to 1.22 million in 2024 [5] - The vice president, Lin Yuecong, saw his salary rise from 971,700 in 2021 to 1.60 million in 2024, which is higher than that of the CEO [6] Leadership Background - Fan Zhanhua, aged 51, has a background in textile engineering and has held various positions in the industry since 2004, becoming the chairman and CEO of the company in 2020 [4] - Lin Yuecong, aged 58, has a diverse background in retail and operations management, currently serving as the vice president of the company [6]

Core Viewpoint - The article highlights the rapid growth of plant-based ingredients in the cosmetics industry, driven by consumer demand for hydration, whitening, and other benefits, alongside supportive government policies for innovation in this area [2][4]. Group 1: Market Trends and Consumer Preferences - The domestic registration of plant-based ingredients reached 23 cases in the first four months of 2025, accounting for 50% of the total cosmetic ingredient registrations during the same period [2]. - Chinese consumers are increasingly focused on ingredient efficacy and safety, moving beyond just popular ingredients to consider formulation, patents, and purity [9][11]. - There is a significant market potential for products that combine plant ingredients with synthetic biology technology, aiming to create gentle yet effective products [9]. Group 2: Technological Innovations - The launch of the "Noble Plant Cell Intelligent Manufacturing Platform" by Noble represents a breakthrough in integrating plant ingredients with modern biotechnology [4][20]. - Two core technologies introduced are GreenCall™ for directed cultivation of plant callus cells and PhytoExo™ PLUS+ for delivering plant callus cell exosomes, addressing challenges in stability and absorption of traditional plant extracts [22][30]. - GreenCall™ technology enhances the synthesis and secretion of functional secondary metabolites, ensuring the purity and safety of plant-derived active ingredients [25][31]. Group 3: Industry Challenges and Opportunities - Traditional plant extracts face challenges such as instability of active ingredients and low transdermal absorption rates [18]. - The application of exosomes in cosmetics is still primarily driven by markets in Korea, Japan, and Europe, indicating a need for further research and application in China [12][31]. - The collaboration between Noble and its affiliated companies aims to leverage advanced technologies to improve the quality and efficacy of plant-based products [19][39]. Group 4: Future Outlook - The establishment of the Noble Plant Cell Intelligent Manufacturing Platform is expected to drive innovation and collaboration within the cosmetics industry, enhancing the development of plant-based ingredients [33][38]. - The platform's capabilities suggest a significant potential for integrating more cutting-edge biotechnologies in the future, positioning Noble as a leader in the transformation of the cosmetics industry [41].

Core Insights - Qing Song Co., Ltd. reported a net profit increase of over 100% year-on-year for 2024, despite a slight decline in revenue [3] - The company's total revenue for the year was approximately 1.94 billion yuan, representing a year-on-year decrease of 1.51% [3] - The net profit attributable to shareholders reached 54.68 million yuan, showing a significant year-on-year growth of 180.02% [3] Executive Compensation - Vice President and Board Secretary Luo Qihui's salary remained unchanged for four consecutive years at 1.185 million yuan, which is lower than other executives [3] - Other executives' salaries include Chairman Fan Zhanhua at 1.222 million yuan, Vice President Lin Yuecong at 1.6054 million yuan, and Executive Vice President Ouyang Ruzheng at 1.383 million yuan [3] - Luo Qihui's salary has been stable since 2020, while Lin Yuecong's salary has shown a year-on-year increase from 2021 to 2024 [3] Regulatory Issues - In December 2023, Qing Song Co., Ltd. received a warning from the Fujian Securities Regulatory Bureau for using evaluation data in disclosure documents without obtaining a formal assessment report [4] - Luo Qihui, as the then Vice President and Board Secretary, was warned alongside Chairman Fan Zhanhua for this violation [4]

Core Viewpoint - Fujian Qingsong Co., Ltd. has completed the registration change and amendment of its Articles of Association, reflecting its new registered address and updated corporate governance structure [1]. Group 1: Company Information - The company held its 13th meeting of the 5th Board of Directors on April 26, 2025, and the annual shareholders' meeting on May 30, 2025, to approve the change of registered address and the corresponding amendments to the Articles of Association [1]. - The company has completed the relevant industrial and commercial registration changes and has obtained a new business license from the Nanping Market Supervision Administration [1]. - The new registered address is located at Room 209, Building 2, Wuyi Yue Hotel Community, No. 515, Chang'an Road, Jianyang District, Nanping City, Fujian Province [1]. Group 2: Corporate Details - The company is a publicly listed joint-stock company with a registered capital of 516,580,886 CNY [1]. - The legal representative of the company is Fan Zhanhua [1]. - The business scope includes investment activities, wholesale and retail of cosmetics, sales of disinfectants (excluding hazardous chemicals), sales of sanitary products and disposable medical supplies, sales of daily chemical products, research and development of bio-chemical products, sales of maternal and infant products, and sales of industrial textile products [1].